当前位置:循环首页>正文

JUPITER试验性别-特异性结果:罗苏伐他汀对高hsCRP和低LDL-C女性心血管事件的一级预防

Rosuvastatin for the Primary Prevention of Cardiovascular Events in Women With Elevated hsCRP and Low LDLC: Sex-Specific Outcomes From the JUPITER Trial

作者:国际循环网   日期:2010/12/8 10:43:45

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

Background Statin therapy in women without manifest cardiovascular disease is controversial given insufficient prior evidence for benefit. We conducted a sex-specific analysis of outcomes in the JUPITER trial, a randomized trial of rosuvastatin 20 mg daily among 17,802 apparently healthy men and women with LDLC <130 mg/dL and hsCRP 2 mg/L.

Samia Mora1; Robert J Glynn2; Paul M Ridker3
1 Harvard Sch of Medicine, Boston, MA
2 Harvard Sch of Public Health, Boston, MA
3 Harvard Sch of Medicine, Boston, MA
    Background Statin therapy in women without manifest cardiovascular disease is controversial given insufficient prior evidence for benefit. We conducted a sex-specific analysis of outcomes in the JUPITER trial, a randomized trial of rosuvastatin 20 mg daily among 17,802 apparently healthy men and women with LDLC <130 mg/dL and hsCRP  2 mg/L.
    Methods 6,801 women  60 years and 11,001 men  50 years were randomized to rosuvastatin or placebo and followed for the trial primary endpoint (first event of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death), and for adverse events. Median follow-up was 1.9 years (maximum 5 years).
    Results At baseline, women were older, had more prevalent hypertension and metabolic syndrome, and less smoking. While the absolute rates (per 100 person-years) of the primary endpoint in rosuvastatin and placebo were lower in women (0.57 and 1.04, respectively) than men (0.88 and 1.54, respectively), the relative risk reduction with rosuvastatin was similar and statistically significant in both women (hazard ratio 0.54, 95% CI 0.37– 0.80, P=0.002) and men (0.58, 95% CI 0.45– 0.73, P<0.001). Consistent with data for men, risk reductions among women were observed for all components of the primary endpoint. The largest benefit for women was for arterial revascularization (hazard ratio 0.24, 95%CI 0.11– 0.51, P <0.001). Rosuvastatin was not associated with a significant increase in myopathy or cancer in either sex. A higher     incidence of physician-reported diabetes occurred in women on rosuvastatin vs placebo (1.59 vs 1.05%, respectively, P=0.008) but not in men (1.48 vs 1.32%, respectively, P=0.29).
   Conclusions Among apparently healthy women with elevated hsCRP but low LDLC, rosuvastatin resulted in similar and significant proportional reductions in cardiovascular events compared with men. The higher incidence of diabetes with rosuvastatin occurred only in women.

 

版面编辑:沈会会  责任编辑:张衡



罗苏伐他汀LDL-C

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530